文献速递胃肠动力与功能性疾病

非活菌益生菌裂解物治疗肠易激综合征:随机双盲安慰剂对照多中心研究

A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-06-29

这项IV期随机双盲安慰剂对照多中心研究纳入389例符合Rome III标准的IBS患者,比较口服非活菌益生菌裂解物(BL)与安慰剂26周的疗效。主要终点基于欧洲药品管理局IBS指南:整体评估改善(GAI)和腹痛改善。BL总体耐受良好。结论认为BL对所有IBS亚型无效,但可能为腹泻型IBS(IBS-D)提供治疗选择,需足够把握度的药物试验验证。

要点

  • BL与安慰剂在IBS整体评估改善和腹痛改善方面无显著差异。
  • 亚组分析提示BL可能对腹泻型IBS(IBS-D)的腹痛和粪便性状有潜在益处。
  • BL治疗耐受性良好。

核心结论

  • BL对所有IBS亚型总体无效,但可能为IBS-D提供治疗选择,需进一步验证。

研究设计与样本

  • IV期随机双盲安慰剂对照多中心(30个中心)平行组研究,纳入389例Rome III标准IBS患者,治疗26周。

主要发现

  • 部分次要结局和敏感性分析提示IBS-D的腹痛指标可能更敏感,但其他亚型未发现。
  • GAI未检测到亚组差异。
  • IBS-D的事后分析显示BL对腹痛随时间反应和粪便性状有潜在 promising 效果。

临床怎么用

  • BL不推荐作为所有IBS亚型的常规治疗。
  • 对于IBS-D患者,BL可能作为潜在治疗选择,但需进一步研究确认。

局限性

  • IBS-D的发现来自事后分析,需足够把握度的药物试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The aim of this study was to investigate the effectiveness of oral treatment with a nonviable probiotic lysate (BL) of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) in patients with irritable bowel syndrome (IBS). METHODS: A phase IV, randomized, double-blind, placebo-controlled, multicenter (30 study sites), parallel group study was conducted in 389 patients of both sexes with IBS according to Rome III criteria. The treatment period was 26 weeks. The participants were allocated to either placebo or BL after a 2-week baseline period. The primary outcome was based on the European Medicines Agency IBS guideline: improvement in global assessment (GAI) and improvement in abdominal pain. RESULTS: Patients (BL, n = 191; placebo, n = 198) had similar baseline values and dropout rates. Overall, the response was similar between BL and placebo for IBS-GAI (17.4% and 14.4%, respectively; P = ·4787) and abdominal pain (42.0% and 35.4%, respectively; P = ·1419). Some secondary outcome measures and sensitivity analyses pointed toward potentially higher sensitivity of the abdominal pain measures in diarrhea-predominant IBS (IBS-D) but not the other subtypes. For the GAI, no subgroup differences were detected. For IBS-D, post hoc analyses for abdominal pain response over time and stool consistency showed potentially promising effects of BL. Finally, the treatment with BL was well-tolerated. CONCLUSIONS: BL is not effective across all IBS subtypes. However, BL may offer a treatment option for IBS-D that needs verification by an adequately powered drug trial; EudraCT-No.: 2012-002741-38.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mack I, Schwille-Kiuntke J, Mazurak N, et al. A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Clin Gastroenterol Hepatol. 2021. PMID: 34214682. doi:10.1016/j.cgh.2021.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。